3,490 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Wetzel Investment Advisors Inc.

Wetzel Investment Advisors Inc. purchased a new position in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 3,490 shares of the company’s stock, valued at approximately $347,000.

A number of other large investors also recently added to or reduced their stakes in MRNA. RB Capital Management LLC increased its position in shares of Moderna by 7.5% during the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock valued at $391,000 after purchasing an additional 158 shares during the last quarter. Synovus Financial Corp lifted its stake in shares of Moderna by 8.0% during the 1st quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock worth $704,000 after purchasing an additional 300 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Moderna by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock valued at $170,121,000 after buying an additional 47,755 shares during the last quarter. Blair William & Co. IL raised its stake in Moderna by 12.4% in the first quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock valued at $2,689,000 after buying an additional 1,724 shares during the last quarter. Finally, Sei Investments Co. raised its stake in Moderna by 41.4% in the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock valued at $10,019,000 after buying an additional 17,031 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $99.05, for a total transaction of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $99.05, for a total transaction of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00. Following the transaction, the director now directly owns 2,131,931 shares of the company’s stock, valued at $231,399,790.74. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,954 shares of company stock valued at $11,533,976. 15.70% of the stock is currently owned by corporate insiders.

Moderna Trading Down 0.6 %

Moderna stock traded down $0.59 during trading on Friday, reaching $101.41. 2,608,152 shares of the company were exchanged, compared to its average volume of 4,160,939. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $144.43. The company has a market capitalization of $38.83 billion, a P/E ratio of -8.16 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The stock’s 50 day simple moving average is $100.35 and its two-hundred day simple moving average is $93.65.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter last year, the business posted $3.61 earnings per share. The firm’s revenue was down 44.9% compared to the same quarter last year. On average, equities research analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. HSBC reiterated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Canaccord Genuity Group raised their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.